文献速递慢性肾脏病肾小球疾病

新型蛋白生物标志物用于慢性肾脏病风险分层与个体化医疗

Novel protein biomarkers for risk stratification and personalized medicine.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

在两项随机对照试验中,评估了尿簇集蛋白与尿EGF对内皮素受体拮抗剂和SGLT2抑制剂的药效学反应。阿曲生坦治疗6周后尿簇集蛋白/肌酐下降46.3%,达格列净减缓尿EGF/肌酐下降且效应因CKD病因异质。这些生物标志物可补充白蛋白尿,反映肾小管损伤与修复。

要点

  • 尿簇集蛋白/肌酐可反映内皮素受体拮抗剂对肾小管损伤的药效反应。
  • 尿EGF/肌酐可反映SGLT2抑制剂对肾小管修复的药效反应。
  • 两标志物补充白蛋白尿,捕捉CKD治疗反应的异质性。

核心结论

  • 尿簇集蛋白和尿EGF是机制导向的药效学生物标志物,分别反映ERA和SGLT2i激活的 distinct 肾内通路。
  • 这些标志物通过捕捉肾小管损伤和修复补充白蛋白尿,提供更全面的CKD治疗效应和异质性生物学评估。

研究设计与样本

  • 评估两项随机CKD试验人群中尿簇集蛋白/肌酐和尿EGF/肌酐的变化。
  • 在SONAR试验的阿曲生坦富集期评估ERA对尿簇集蛋白/肌酐和ET-1的影响。
  • 在DAPA-CKD试验中评估SGLT2i对不同CKD病因、糖尿病状态和血糖控制下尿EGF/肌酐的影响。
  • 利用肾活检单细胞RNA测序数据检查尿EGF/肌酐与肾内EGF mRNA表达关联。

主要发现

  • 阿曲生坦治疗6周后,尿簇集蛋白/肌酐下降46.3%(95%CI:-57.8至-37.1),血清ET-1升高23.4%(95%CI 19.2-27.4)。
  • DAPA-CKD中达格列净减缓1年内尿EGF/肌酐下降,效应因CKD病因异质:糖尿病肾病相对增加最大,肾小球肾炎和高血压肾病无效应。
  • 2型糖尿病和基线HbA1c较高者效应更大;肾小管EGF mRNA表达与尿EGF/肌酐正相关。

临床怎么用

  • 尿簇集蛋白/肌酐和尿EGF/肌酐可作为机制导向的药效学标志物,辅助评估ERA和SGLT2i在CKD中的治疗反应。
  • 在糖尿病肾病中监测尿EGF/肌酐变化可能有助于识别SGLT2i治疗获益更明显的人群。
  • 结合白蛋白尿与肾小管标志物可更全面评估CKD治疗效应异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Albuminuria is widely used to monitor chronic kidney disease (CKD) and treatment response but is subject to variability and primarily reflects glomerular injury. Urinary clusterin and epidermal growth factor (uEGF) are associated with tubular injury and repair, respectively, and may serve as mechanism-informed pharmacodynamic biomarkers. We investigated responses of urinary clusterin and uEGF to endothelin receptor antagonists (ERAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), respectively, in CKD. METHODS: We evaluated changes in urinary clusterin-to-creatinine ratio (uCLU/Cr) and uEGF-to-creatinine ratio (uEGF/Cr) in two randomized CKD trial populations. Effects of ERA on uCLU/Cr and endothelin-1 (ET-1) were assessed during the atrasentan enrichment phase of SONAR (Study of Diabetic Nephropathy with Atrasentan), and effects of SGLT2i on uEGF/Cr were examined in DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) across different CKD etiologies, diabetes status, and glycemic control. Associations between uEGF/Cr and intrarenal EGF messenger RNA (mRNA) expression were examined using kidney biopsy single-cell RNA sequencing data. RESULTS: After 6 weeks of treatment with atrasentan, uCLU/Cr decreased by 46.3% (95% confidence interval [CI]: -57.8 to -37.1), while serum ET-1 increased by 23.4% (95% CI 19.2-27.4). There were no effects on serum clusterin and only a numerical decrease in urinary ET-1. Baseline uCLU/Cr correlated significantly with urinary ET-1 (Pearson r = 0.65, P < .0001). In DAPA-CKD, dapagliflozin attenuated the decline in uEGF/Cr over 1 year, with heterogeneity across CKD etiologies. Relative increases were greatest in diabetic kidney disease and absent in glomerulonephritis and hypertensive nephropathy. Similarly, effects were larger in those with type 2 diabetes and higher baseline HbA1c. Tubular EGF mRNA expression correlated positively with uEGF/Cr. CONCLUSIONS: Urinary clusterin and uEGF are mechanism-informed pharmacodynamic biomarkers reflecting distinct intrarenal pathways engaged by ERA and SGLT2i therapy, respectively. These biomarkers complement albuminuria by capturing tubular injury and repair, providing a more comprehensive biological assessment of treatment effects and heterogeneity in CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Moedt E, Ju W, Nair V, et al. Novel protein biomarkers for risk stratification and personalized medicine. Nephrol Dial Transplant. 2026. PMID: 41874429. doi:10.1093/ndt/gfag068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。